Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, talk about the emerging treatments for MM, including monoclonal antibodies, 2nd-generation protease inhibitors, and targeted therapies. These changes pose challenges to healthcare providers struggling to keep up with these changes, but this is good news for patients with expanding treatment options.
Family caregivers are integral to patient care in oncology, including attending appointments in which care options are discussed or decisions are made. The involvement of caregivers in oncology care will only increase as practice recommendations and policies are encouraging their inclusion. Yet, we do not fully understand the treatment decision-making (TDM) dynamics between patients and their caregivers or the capacity among caregivers to make care decisions. Further, caregivers' communication with a patient or healthcare team (HCT) remains underexplored in understanding shared decision-making.